Using Visible Residue Limits for Introducing New Compounds into a Pharmaceutical Research Facility

Six winners and two honorable mentions were revealed at ISPE’s Europe Annual Conference in London.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new tariff policies.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with the current standard of care, according to a phase III trial.

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.